Acquisition adds precision micro-molding, insert molding, and advanced machining and tooling to Resonetics' portfolio of precision manufacturing capabilities.

NASHUA, N.H., Sept. 29, 2025 /PRNewswire/ -- Resonetics announced today that it has acquired Eden Holdings (Eden), comprising both Eden Manufacturing and Eden Tool, a precision manufacturer specializing in injection molding and micro machining solutions for critical medical devices. The acquisition adds micro-molding, insert-molding, and advanced machining and tooling, complementing Resonetics' established metal processing capabilities, while also expanding the Swiss machining and EDM machining offerings. These additions enhance Resonetics' portfolio of specialized MedTech capabilities to serve high-growth markets including among others robotic surgery, minimally invasive surgery, electrophysiology, and rapid diagnostics.

Founded in 2000, Eden has built a strong reputation for its expertise in precision tooling and machining, which evolved into high precision micro and insert molding for critical medical devices. The company also specializes in Class 101 production tooling for the MedTech industry, delivering molds and components that demand uncompromising precision, complex geometries, and exceptional quality. Eden's engineering-driven approach to mold design and manufacturing ensures consistent, reliable solutions that meet the rigorous standards of leading MedTech OEMs.

"With the addition of Eden, we are enhancing our ability to deliver integrated solutions across materials and technologies. Eden's strength in injection molding and precision tooling is a critical addition, bringing valuable new capabilities that complement our metal processing expertise across our entire portfolio and enable us to deliver a more integrated offering to our customers," said Kevin Kelly, CEO of Resonetics.

"Joining Resonetics gives Eden access to greater resources and a global platform to better serve our customers. We're excited to combine our precision tooling, insert molding, and micro-molding expertise with Resonetics' advanced technologies to provide even more value to the medical device industry," said David Tomic, President of Eden.

The acquisition of Eden expands Resonetics' polymer capabilities and adds another key area of expertise, reinforcing its position as a differentiated partner delivering micro manufacturing solutions for complex medical devices.

About Resonetics

Founded in 1987, Resonetics is a pioneer in advanced engineering and manufacturing solutions for the medical device industry. Resonetics is a leader in laser processing, nitinol manufacturing, thin-wall stainless steel, nitinol & precious metal tubing, and photochemical machining. With strategically located LightSpeed Labs^® and AGILE Product Development^® centers, Resonetics is committed to quality, speed, innovation, and a great customer experience. The company is ISO 13485:2016 certified with 17 facilities and more than 3,000 associates in the United States, Canada, Costa Rica, Israel, and Switzerland. Resonetics is backed by leading private equity firms Carlyle and GTCR. Learn more at www.resonetics.com.

About GTCR

Founded in 1980, GTCR is a leading private equity firm that invests behind The Leaders Strategy^™ – finding and partnering with management leaders in core domains to identify, acquire and build market-leading companies through organic growth and strategic acquisitions. GTCR is focused on investing in transformative growth in companies in the Business & Consumer Services, Financial Services & Technology, Healthcare and Technology, Media & Telecommunications sectors. Since its inception, GTCR has invested more than $30 billion in over 280 companies, and the firm currently manages $45 billion in equity capital. GTCR is based in Chicago with offices in New York and West Palm Beach. For more information, please visit www.gtcr.com. Follow us on LinkedIn.

About Carlyle

Carlyle (NASDAQ: CG) is a global investment firm with deep industry expertise that deploys private capital across three business segments: Global Private Equity, Global Credit, and Carlyle AlpInvest. With $453 billion of assets under management as of March 31, 2025, Carlyle's purpose is to invest wisely and create value on behalf of its investors, portfolio companies, and the communities in which we live and invest. Carlyle employs more than 2,300 people in 29 offices across four continents. Further information is available at www.carlyle.com. Follow Carlyle on X @OneCarlyle and LinkedIn at The Carlyle Group.

View original content to download multimedia:https://www.prnewswire.com/news-releases/resonetics-acquires-eden-holdings-adding-injection-molding-to-its-capabilities-302568600.html

SOURCE Resonetics, LLC

Resonetics® Acquires Eden Holdings, Adding Injection Molding to its Capabilities